Status:
ENROLLING_BY_INVITATION
Platelet Rich Plasma in the Prevention of Adhesion Reformation
Lead Sponsor:
Fu Xing Hospital, Capital Medical University
Conditions:
Intrauterine Adhesion
Asherman Syndrome
Eligibility:
FEMALE
20-40 years
Phase:
NA
Brief Summary
Asherman syndrome, which occurs after trauma to the basalis layer of the endometrium. It seems that the role of postoperative platelet rich plasma（PRP）therapy in the prevention of recurrence of IUA is...
Detailed Description
Asherman syndrome, which occurs after trauma to the basalis layer of the endometrium. It seems that the role of postoperative platelet rich plasma（PRP）therapy in the prevention of recurrence of IUA is...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Asherman's syndrome. AFS score \>7.
Exclusion
- Leiomyoma;
- Endometrial polyps;
- Ppolycystic ovarian syndrome (PCOS).
Key Trial Info
Start Date :
October 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT06608407
Start Date
October 10 2023
End Date
June 1 2025
Last Update
March 11 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Fu Xing Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100073
2
Fuxing hospital
Beijing, Beijing Municipality, China, 100073